Adding digestive enzymes to usual diabetes treatment
Part of Hormones & metabolism clinical trials.
This study tests adding a digestive enzyme (pancreatin) to your usual diabetes medicines to see if it helps control blood sugar better. You may benefit if your current treatment is working, but your A1C is still not in the target range.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes for at least 12 months.
- You are between 35 and 75 years old.
- You are currently on diabetes medications (pills or insulin).
- Your A1C (average blood sugar) is between 6.5% and 9.0%.
- You have not taken certain newer diabetes drugs (like Ozempic or Januvia) in the last 3 months.
- You have no history of pancreatic surgery or pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding certain diabetes pills (GLP-1 receptor agonists or SGLT inhibitors) to insulin is safe and helpful for adults with type 1 diabetes. Doctors will check your glucose monitor data to see how well this works.
This study looks at how chronic pancreatitis affects blood sugar and digestion. It tests if your body makes enough enzymes and how your sugar control changes over time.
This study looks at how the pancreas affects blood sugar and diabetes. It may help find better ways to prevent or treat type 2 diabetes.
This study tests whether adding a diabetes pill called pioglitazone to your current treatment (which includes an SGLT2 inhibitor and insulin) can lower your HbA1c (average blood sugar) further and prevent a dangerous rise in blood ketones, a byproduct that can cause serious complications. If it works, this combination may help improve blood sugar control in people with type 1 diabetes.
This study looks at whether adding oral diabetes medications to insulin therapy can help people with type 1 diabetes manage their blood sugar better. It compares people who take both insulin and oral drugs with those who take only insulin.
This study tests whether adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a thiazolidinedione (TZD), or a combination of both to your current DPP4 inhibitor-based treatment can improve blood sugar control in type 2 diabetes. It aims to find the best add-on option for people who need extra help managing their diabetes.
Hear when a new Type 2 Diabetes (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.